[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]

@FierceBiotech Avatar @FierceBiotech FierceBiotech

FierceBiotech posts on X about has been, $bmy, $regn, vivo the most. They currently have XXXXXXX followers and XX posts still getting attention that total XXXXX engagements in the last XX hours.

Engagements: XXXXX #

Engagements Line Chart

Mentions: XX #

Mentions Line Chart

Followers: XXXXXXX #

Followers Line Chart

CreatorRank: XXXXXXX #

CreatorRank Line Chart

Social Influence #


Social category influence stocks XXXXX% travel destinations XXXX% technology brands XXX% finance XXX%

Social topic influence has been 3.61%, $bmy #4, $regn 1.2%, vivo 1.2%, deeper 1.2%, blockbuster 1.2%, $nvo 1.2%, $kzr 1.2%, $mrk #11, london XXX%

Top accounts mentioned or mentioned by @braincures @polaronfinance @_joebaffoe @pennysunited @persimmonti @mateosagan @dtrmweihe @agingdoc1 @eathopepray @longevity_agent @heatherlandi @johnmeta_ @grok @fmi_research @biotechanalysst @joserestonva @chuminhua432 @acfer12 @lineagecell @biogerontology

Top assets mentioned Bristol-Myers Squibb Co (BMY) Regeneron Pharmaceuticals Inc (REGN) Novo-Nordisk (NVO) Merck & Co., Inc. (MRK) Denali Therapeutics Inc. Common Stock (DNLI) Eli Lilly and Company (LLY) Gilead Sciences, Inc. (GILD) Sanofi (SNY)

Top Social Posts #


Top posts by engagements in the last XX hours

"Regeneron is racing to regulators after reporting a phase X win in an ultrarare disease. $REGN"
X Link @FierceBiotech 2025-09-17T14:11Z 101.7K followers, 2773 engagements

"Ono Pharmaceuticals EP4 antagonist hit the primary progression-free survival endpoint in a phase X trial in patients with gastric cancer"
X Link @FierceBiotech 2025-10-09T14:52Z 101.7K followers, 3927 engagements

"Pushing deeper into in vivo cell therapies BMS hasagreed to pay $XXX billion to buy Orbital Therapeutics for a pipeline led by a preclinical CD19 autoimmune program. $BMY"
X Link @FierceBiotech 2025-10-10T15:17Z 101.7K followers, 2184 engagements

"Bristol Myers Squibb is pointing to a XX% overall response rate from one cohort of an early-stage study of its EGFRxHER3 ADC as evidence the pharma can stay ahead of the competition. $BMY"
X Link @FierceBiotech 2025-10-17T14:53Z 101.7K followers, 1781 engagements

"Novo Nordisk hasstruck a deal to buy Akero Therapeutics for up to $XXX billion teeing up a showdown with Roche and others in a blockbuster liver disease market"
X Link @FierceBiotech 2025-10-09T14:52Z 101.7K followers, 1929 engagements

"After Omeros hit pause on developing its MASP-3 inhibitor zaltenibart Novo Nordisk is offering up to $XXX billion to scoop the rare disease drug. $NVO"
X Link @FierceBiotech 2025-10-15T14:34Z 101.7K followers, 1972 engagements

"A regulatory impasse and the FDAs cancellation of a meeting to discuss the next steps in a R&D program have prompted Kezar Life Sciences to lay off staff and explore strategic alternatives. $KZR"
X Link @FierceBiotech 2025-10-17T13:12Z 101.7K followers, 1578 engagements

"Less than two years after breaking ground on a $XXX billion R&D center and future U.K. headquarters in London Merck & Co. is bailing on the project and discontinuing all research operations in Britain citing an unwelcoming business environment. $MRK"
X Link @FierceBiotech 2025-09-10T19:59Z 101.7K followers, 77.3K engagements

"The FDA has delayed an approval decision for Denali's enzyme replacement therapy designed to treat a rare genetic disorder called Hunter syndrome. The decision has been pushed back three months to April X. $DNLI"
X Link @FierceBiotech 2025-10-14T12:46Z 101.7K followers, 2278 engagements

"Lilly shared oral GLP-1 data from two of the remaining three trials in its diabetes program racking up wins against placebo and AstraZenecas Farxiga. $LLY"
X Link @FierceBiotech 2025-10-15T15:01Z 101.7K followers, 1734 engagements

"Gilead Sciences and Arcus Biosciences anti-TIGIT antibody domvanalimab has been tied to median overall survival of close to XX months keeping alive one of the last remaining hopes for this once-hyped modality"
X Link @FierceBiotech 2025-10-13T18:30Z 101.7K followers, 3603 engagements

"Bristol Myers Squibb hasagreed to pay $XXX billion to buy Orbital Therapeutics for a pipeline led by a preclinical CD19 autoimmune program"
X Link @FierceBiotech 2025-10-10T14:30Z 101.7K followers, 3686 engagements

"The 2025 Nobel Prize in Physiology or Medicine has been awarded to three pioneering immunologists for their work on regulatory T cells including two who conducted their winning work at a British biotech"
X Link @FierceBiotech 2025-10-06T13:13Z 101.7K followers, 2640 engagements

"4. Astellas walks away from gene therapy pact with Taysha before pivotal trial launch X. I-Mab undergoes makeover with new name strategy asset and Hong Kong IPO plans"
X Link @FierceBiotech 2025-10-17T16:02Z 101.7K followers, 1311 engagements

"Big day for biotech newsFierce Biotech has you covered with the largest stories of the morning below: X. ESMO: BMS looks to 'stay ahead of the competition' with ADC's XX% response rate in early-stage trial X. FDA names nine first recipients of 1- to 2-month priority review vouchers X. Licensing galore: Roche Chugai and Kite strike up deals and"
X Link @FierceBiotech 2025-10-17T15:57Z 101.7K followers, 2317 engagements

"The FDA hashanded out the first nine national priority vouchers positioning companies including Merck KGaA Regeneron and Sanofi to complete the approval process in one to two months"
X Link @FierceBiotech 2025-10-17T13:56Z 101.7K followers, 1621 engagements